Compare LILAK & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LILAK | HROW |
|---|---|---|
| Founded | 2017 | 1998 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Cable & Other Pay Television Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | N/A | N/A |
| Metric | LILAK | HROW |
|---|---|---|
| Price | $7.71 | $44.47 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | $8.20 | ★ $68.86 |
| AVG Volume (30 Days) | ★ 944.0K | 581.9K |
| Earning Date | 02-18-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,433,000,000.00 | $250,042,000.00 |
| Revenue This Year | $1.37 | $38.96 |
| Revenue Next Year | N/A | $43.38 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 47.83 |
| 52 Week Low | $4.23 | $20.85 |
| 52 Week High | $9.13 | $54.85 |
| Indicator | LILAK | HROW |
|---|---|---|
| Relative Strength Index (RSI) | 51.50 | 40.33 |
| Support Level | $7.34 | $44.55 |
| Resistance Level | $8.11 | $47.86 |
| Average True Range (ATR) | 0.28 | 2.84 |
| MACD | 0.10 | -0.80 |
| Stochastic Oscillator | 69.81 | 5.95 |
Liberty Latin America Ltd is a telecommunications company. It is a provider of video, broadband internet, fixed-line telephony, and mobile services to residential and business customers. The company's reportable segments include C&W Caribbean, Liberty Networks, C&W Panama, VTR, Liberty Puerto Rico and Liberty Costa Rica. The company generates the majority of its revenue from C&W Caribbean, and Liberty Puerto Rico segments.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company's FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company's ophthalmology-focused pharmaceutical compounding business.